Genta Withdraws NDA For Genasense In Melanoma
The company has requested a meeting with FDA to identify the next steps for further development. The move coincides with a restructuring at Genta to focus resources on the Genasense program.
The company has requested a meeting with FDA to identify the next steps for further development. The move coincides with a restructuring at Genta to focus resources on the Genasense program.